Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11735-40. PubMed Abstract

  
Comments on Paper and Primary News
  Primary News: BACE Goes Rafting after APP

Comment by:  Gerard Drewes (Disclosure)
Submitted 26 September 2003  |  Permalink Posted 26 September 2003

Despite the problems with chemical tractability, β-secretase (BACE) remains one of the most promising targets for the treatment of Alzheimer's disease. It has been known for some time that APP, BACE, and γ-secretase (presenilins and associated proteins) all localize, at least partially, to membrane domains enriched in cholesterol called rafts. This is of interest because the statins, blockbuster drugs that lower cholesterol, inhibit the generation of Aβ peptides in cultured cells. Kai Simons and coworkers have proposed that APP inside rafts may be "bad" because it is mainly cleaved by β-secretase, whereas APP outside rafts may be "good" because it is mainly processed by α-secretase. Cordy et al. provide additional evidence for this hypothesis. They demonstrate an increase of Aβ secretion upon transfection of cells with a BACE construct targeted to rafts by an artificial GPI anchor. Lovastatin treatment abolishes this increase. The current study was performed in a neuroblastoma cell line, but the effects of protein sorting may be even more severe in a mature neuron where transport...  Read more

  Primary News: BACE Goes Rafting after APP

Comment by:  Vincent Marchesi, ARF Advisor
Submitted 28 September 2003  |  Permalink Posted 28 September 2003
  I recommend this paper

I think this issue is worth exploring,but I am concerned that the ability of a GPI-BACE chimera to cleave APP may be too artificial a model to tell us much about how the authentic BACE behaves. GPI-linked peptides would be expected to partition in rafts or raft-like domains. The studies of the Simons group also claim that an endocytosis reaction is important for BACE function, a point not considered by Cordy et al.

View all comments by Vincent Marchesi

  Primary News: BACE Goes Rafting after APP

Comment by:  Gerard Drewes (Disclosure)
Submitted 29 September 2003  |  Permalink Posted 29 September 2003
  I recommend this paper

  Primary News: BACE Goes Rafting after APP

Comment by:  Dora M. Kovacs, ARF Advisor
Submitted 29 September 2003  |  Permalink Posted 29 September 2003

Increasing evidence from biochemical, epidemiological, and genetic studies links cholesterol levels to Aβ production and the onset of AD pathology. Total cellular cholesterol can regulate Aβ generation, as evidenced by decreased Aβ levels in cells treated with statins, which inhibit cholesterol intake and synthesis. Intracellular distribution and/or trafficking of cholesterol are also gaining more and more support as potentially valid targets for indirect antiamyloid therapy. Altered cholesterol trafficking through the Niemann-Pick C1 compartment and altered cholesterol distribution into cholesteryl-ester droplets and lipid rafts, all affect APP processing into Aβ. Anthony Turner, Joanna Cordy and colleagues show that targeting BACE1 to lipid rafts is sufficient to elevate secreted Aβ levels, further strengthening the relevance of intracellular compartmentation of cholesterol in Aβ generation. Although Kai Simons and colleagues, Kumar Sambamurti and colleagues, and others have previously shown that lipid rafts are important players in at least BACE1-mediated processing of APP,...  Read more
  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad